NEW YORK (GenomeWeb) – Leerink Partners and Canaccord Genuity today initiated coverage of HTG Molecular Diagnostics. Leerink gave the firm's shares an "Outperform" rating and an $18 price target while Canaccord gave them a "Buy" rating with a $17 price target.

Canaccord analyst Mark Massaro said in a report that HTG has the opportunity to be a leading player in the approximately $27 billion molecular profiling market, especially for oncology, which he estimated was more than $15 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.